Disposition of lorazepam in human beings: Enterohepatic recirculation and first‐pass effect

@article{Herman1989DispositionOL,
  title={Disposition of lorazepam in human beings: Enterohepatic recirculation and first‐pass effect},
  author={Robert J. Herman and J D Van Pham and Cameron Szakacs},
  journal={Clinical Pharmacology \& Therapeutics},
  year={1989},
  volume={46}
}
The effects of neomycin and cholestyramine on the disposition of lorazepam was examined in seven healthy drug‐free men. Half‐life as determined for the oral route was, in all subjects, 15% to 35% less than that determined for the intravenous route. Free oral clearance was slightly but not significantly less than free systemic clearance, but the ratio of the AUC of lorazepam glucuronide corrected for dose was twofold greater by the oral route. Urinary recoveries also differed (71.6% and 50.4… Expand
Lorazepam‐Valproate Interaction: Studies in Normal Subjects and Isolated Perfused Rat Liver
Summary: Valproate (VPA) has been shown to interact with all the major antiepileptic drugs (AEDs) through two mechanisms of action: displacement from albumin binding sites and inhibition of drugExpand
Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples.
TLDR
Pregnancy changes the pharmacokinetics of lorazepam, with an increase in the apparent distribution volume, an increaseIn apparent oral clearance, and a reduction of elimination half-life, with a possible reduction in the plasma concentrations of drugs depending on glucuronidation capacity as the major metabolic pathway. Expand
Effect of neurotrauma on hepatic drug clearance
TLDR
It is suggested that hepatic oxidative and conjugative metaboHsm increase significantly over time in patients after acute head injury and an awareness of the potential for pharmacokinetic alterations in similarly metabolized drugs used for patients with severe head injuries is recommended. Expand
Role of enterohepatic recirculation in drug disposition: cooperation and complications
TLDR
Critically appraise the mechanisms of bile formation, factors affecting biliary drug elimination, methods to estimate biliary excretion of drugs, EHC, multiple peak phenomenon and its modeling. Expand
The effect of colestipol and cholestyramine on the systemic clearance of intravenous ibuprofen in rabbits
TLDR
The changes in the pharmacokinetic parameters are compatible with an acceleration of ibuprofen elimination induced by oral administration of cholestyramine and not by colestipol, thought to be due to augmentation of net biliary excretion through enteric binding. Expand
Decreased Systemic Clearance of Lorazepam in Humans With Spinal Cord Injury
TLDR
It is concluded that decreased systemic CL and the altered terminal elimination profile of LRZ are attributable to the pathophysiology of SCI. Expand
Effects of oral administration of colestipol and cholestyramine on the pharmacokinetics of ketoprofen administered intramuscularly in man
The effect of oral administration of the anion exchange resins colestipol hydrochloride (10 g) or cholestyramine (8 g) on the systemic clearance and other pharmacokinetic parameters ofExpand
Interruption of the enterohepatic circulation of indomethacin by cholestyramine in rabbits
TLDR
Cholestyramine administration accelerates the systemic elimination of indomethacin, thought to be due to augmentation of net biliary excretion through enteric binding. Expand
Disposition of Lorazepam in Gilbert's Syndrome: Effects of Fasting, Feeding, and Enterohepatic Circulation
TLDR
Lorazepam clearances were 20–40% lower in patients with Gilbert's syndrome compared with normals when studied fasting and with neo/chol, or fed and in the control state (P < 0.05 for both). Expand
Disposition of lorazepam in diabetes: differences between patients treated with beef/pork and human insulins
TLDR
The pharmacokinetics of lorazepam was not altered in patients with insulin-dependent diabetes mellitus, however, it is possible that there are differences in the rate and extent of hepatic glucuronidation and enterohepatic circulation in diabetic patients and between diabetics treated with beef/pork insulin and non-diabetic controls. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
First pass conjugation and enterohepatic recycling of oxazepam in dogs; intravenous tolerance of oxazepam in propylene glycol.
TLDR
In a dog with a chronic biliary fistula 15 mg of oxazepam was given intravenously on two occasions and findings indicate enteral hydrolysis of the conjugates, and a marked enterohepatic recycling or oxzepam. Expand
Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam.
TLDR
Biotransformation to a pharmacologically inactive glucuronide metabolite appeared to be the major mechanism of lorazepam clearance and its metabolites in body fluids were determined by appropriate analytic techniques. Expand
Hepatic and extrahepatic glucuronidation of lorazepam in the dog
TLDR
It is concluded that the liver is the major site for lorazepam metabolism in dogs; however, appreciable extrahepatic metabolism occurs, partly in non hepatic components of the splanchnic organs which act as a reservoir during drug distribution. Expand
Clinical Pharmacokinetics of Oxazepam and Lorazepam
TLDR
3-hydroxy benzodiazepine derivatives used as sedatives and anxiolytics and Oral and intramuscular lorazepam are rapidly absorbed, with systemic availability averaging 90 % or more. Expand
Pharmacokinetics and bioavailability of ranitidine in humans.
  • R. Miller
  • Chemistry, Medicine
  • Journal of pharmaceutical sciences
  • 1984
TLDR
It is proposed that ranitidine accumulates mainly from the systemic circulation into a depot from which drug and bioreversible drug are spontaneously released in response to food intake. Expand
Effects of aging and liver disease on disposition of lorazepam
TLDR
It is concluded that the degree of impairment, if any, in the metabolism of lorazepam in patients with liver disease is considerably less than that of certain other drugs including related benzodiazepines. Expand
Clinical pharmacokinetics of lorazepam: a review.
TLDR
The clinical pharmacokinetics of lorazepam indicate that it is rapidly and readily absorbed, reaching peak concentrations in the blood proportional to the dose approximately 2 hours after oral administration, and the active drug and the glucuronide conjugate are completely eliminated from the blood within 1 week following the last dose. Expand
Lorazepam kinetics in the elderly
TLDR
The aging process is associated with small changes in the kinetics of lorazepam, as in the case of young individuals, which leads to rapid and nearly complete absorption into the systemic circulation. Expand
The enterohepatic circulation of oxazepam‐O‐glucuronide in guinea‐pigs
TLDR
Oxazepam-0-glucuronide was purified from rabbit urine by two chloroform extractions and two passages through activated charcoal columns, followed by thinlayer chromatography on silica gel preparative plates as described in detail elsewhere. Expand
Clinical pharmacokinetics of lorazepam. III. Intravenous injection. Preliminary results.
Four healthy male volunteers received 5 mg lorazepam as a single intravenous injection. Concentrations of lorazepam and its glucuronide metabolite were determined in multiple venous blood samplesExpand
...
1
2
3
4
...